Aspen Pharmacare chair Kuseni Dlamini will step down from the pharmaceutical group’s board in December 2026. Veteran director and former banking executive Ben Kruger will succeed him as chair. Aspen said Dlamini would not make himself available for re-election as a director. The company’s annual general meeting is scheduled for December. His departure will conclude a 14-year tenure on the…
Tag: Stephen Saad
-
Aspen Pharmacare Asset Disposals: Future Opportunities
Multinational pharmaceutical giant Aspen Pharmacare is prepared to further streamline its global operations. While the company has not officially hoisted a “for sale” sign, leadership has indicated it remains open to further Aspen Pharmacare asset disposals if the price is right. This strategic openness follows the landmark sale of its Asia-Pacific (APAC) division. The R26.5 billion transaction serves as a…
-
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare has officially closed the chapter on its leveraged era. For the first time since the company was founded in 1997, CEO Stephen Saad has confirmed the group is debt-free. This significant milestone follows the massive sale of its Asia-Pacific operations (excluding China) to BGH Capital. The deal, concluded at the end of last year, was valued at A$2.37…
-
Aspen Pharmacare Dispute Ends with R500m Settlement
Aspen Pharmacare is set to receive a R500m windfall following the resolution of a damaging legal battle with an undisclosed manufacturing client. This closes a seven-month chapter of significant financial uncertainty for Africa’s largest pharmaceutical producer. In a statement, Aspen advised shareholders that the dispute had been settled. The counterparty is required to pay the R500m “before December 1 2025,…
-
Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen targeting Mounjaro expansion will bring the high-demand drug Mounjaro to Sub-Saharan Africa. Mounjaro is also known as tirzepatide. Launches across the continent are anticipated in 2026. CEO Stephen Saad confirmed this plan. He announced it in his annual letter to shareholders. The move follows major success in South Africa. It also comes after a new regulatory approval. This approval…
-
Aspen Unlocking Value with New Manufacturing Strategies
Aspen Pharmacare’s CEO, Stephen Saad, has declared that all hands are on deck to overhaul the group’s manufacturing business. He identified the performance of its sterile unit as a significant drag on earnings. This underperformance has caused the market to undervalue the company. This move is part of Aspen’s effort to unlock value for its stakeholders and enhance its market…
-
Aspen secures licensing agreement to enter GLP-1 market
Aspen Pharmacare’s CEO, Stephen Saad, has celebrated the company’s new licensing agreement to enter the rapidly expanding GLP-1 agonist market. He said this milestone marks a “significant coup” for the company, enabling it to prepare for the market by 2026 and capitalise on the anticipated demand for diabetes and obesity treatment solutions. The global GLP-1 market, driven by increased demand…